Apogee Therapeutics, Inc.
APGE
Kedudukan dalam Saham
#2350
Apogee Therapeutics, Inc. is a biotechnology firm, operating via its... Apogee Therapeutics, Inc. is a biotechnology firm, operating via its subsidiary, dedicated to advancing biologic treatments for conditions such as atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and a range of other inflammatory and immunological disorders. Its primary focus includes APG777, a subcutaneous (SQ) monoclonal antibody (mAb) engineered for an extended half-life to treat AD, and APG808, a similarly formulated SQ extended half-life mAb targeting COPD. Furthermore, its earlier-stage pipeline features APG990, another SQ extended half-life mAb designed for AD, and APG222, comprising extended half-life subcutaneous antibodies also aimed at AD. Established in 2022, the company maintains its headquarters in Waltham, Massachusetts.
Harga Saham
$135.07
Disegerakkan terakhir: 2026-09-04
Modal Pasaran
$8.36B
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
137.21%
Negara
US
Perdagangan Apogee Therapeutics, Inc. (APGE)
Kategori
Healthcare
Nisbah P/S bagi Apogee Therapeutics, Inc. (APGE)
Nisbah P/S pada October 2026 TTM: 0.00
Menurut laporan kewangan dan harga saham terkini Apogee Therapeutics, Inc., nisbah P/S semasa (TTM) ialah 0.00. Pada akhir 2023, nisbah P/S syarikat ialah 0.00.
Sejarah nisbah P/S untuk Apogee Therapeutics, Inc. dari 2022 hingga 2026
Nisbah P/S pada akhir setiap tahun
| Tahun | Nisbah P/S | Ubah |
|---|---|---|
| 2026 (TTM) | 0.00 | 0.00% |
| 2024 | 0.00 | 0.00% |
| 2023 | 0.00 | 0.00% |
| 2022 | 0.00 | 0.00% |
Nisbah P/S untuk syarikat atau pesaing yang serupa
| Syarikat | Nisbah P/S | Perbezaan Nisbah P/S | Negara |
|---|---|---|---|
| 10.02 | - |
US
|
|
| 40.55 | - |
US
|
|
| 3.96 | - |
AU
|
|
| - | - |
CH
|
|
| 10.15 | - |
NL
|
